Re: MSD and Huang
Very interesting. Could $100M be heading to ZIOP at $7 or $8 a share. This would be a good way to raise capital at a much higher price than a normal secondary. Might be a long shot but if Huang believes He could use the money to help partner with ZIOP TCRs in China for an upfront amount. That would push the cash runway to 2023 and not dilute current shareholders.
It sure seems odd that our Chairman and biggest shareholder would raise $200M for biotech investment unless it was related to ZIOP in some way. Is that possible?